Adicet Bio, Inc. (ACET) Research

Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.

Market snapshot

Symbol
ACET
Price
$8.10
Day change
0.00%
Market cap
$75.7M
P/E ratio
-0.80x
52-week range
6.01-17.44
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$18.00

Peer companies

  • Acrivon Therapeutics, Inc. Common Stock (ACRV)
  • Adagene Inc. (ADAG)
  • CervoMed Inc. (CRVO)
  • Gain Therapeutics, Inc. (GANX)
  • Werewolf Therapeutics, Inc. (HOWL)
  • Immunic, Inc. (IMUX)
  • IO Biotech, Inc. (IOBT)
  • Lite Strategy, Inc. (LITS)

Recent insider activity

  • RA CAPITAL MANAGEMENT, L.P. — J-Other (250000 shares) on 2026-04-27
  • RA CAPITAL MANAGEMENT, L.P. — J-Other (250000 shares) on 2026-04-27
  • RA CAPITAL MANAGEMENT, L.P. — P-Purchase (74751 shares) on 2026-02-20
  • RA CAPITAL MANAGEMENT, L.P. — P-Purchase (74268 shares) on 2026-02-19
  • RA CAPITAL MANAGEMENT, L.P. — P-Purchase (74577 shares) on 2026-02-18

Open Adicet Bio, Inc. (ACET) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.